VCAM1 and cancer: Taken together, these results show that CBP501 can suppress ABCG2 expression in cancer cells by suppressing cell-cell interactions between cancer cells expressing VCAM-1 and macrophages expressing VLA-4, at least by reducing the expression levels of these surface molecules.